Business UpdateMay 20, 2026, 06:37 AM
Haemonetics Receives FDA Clearances for Persona PLUS, VASCADE MVP XL
AI Summary
Haemonetics, a global medical technology company, provided an overview of its three principal reporting segments: Plasma, Blood Center, and Hospital. The company focuses on Plasma and Hospital for growth, noting recent FDA clearances for its NexSys PCS Plasma Collection System with Persona PLUS technology and an expanded indication for the VASCADE MVP XL vascular closure system. In fiscal 2025, the company divested its Whole Blood product line to align resources with higher-margin opportunities.
Key Highlights
- Received FDA 510(k) clearance for NexSys PCS Plasma Collection System with Persona PLUS technology in fiscal 2026.
- Received FDA approval to expand VASCADE MVP XL indication for 10-14F ID and up to 17F OD sheaths in fiscal 2026.
- Divested the Whole Blood product line within the Blood Center business in fiscal 2025.
- Plasma business represented 39.3% of total revenue in fiscal 2026.
- Hospital business represented 44.1% of total revenue in fiscal 2026.
- Blood Center business represented 16.6% of total revenue in fiscal 2026.
- Completed U.S. customer conversion to Express Plus and Persona technologies by end of fiscal 2026.
Price Impact
More from HAE